Profile
Dean Hakanson held several positions in the healthcare industry, including Vice President-Healthcare Access at Bristol Myers Squibb Co., Head-Payer Field Team at Genentech, Inc., Vice President & Head-Medical Western US Region at Novartis AG, Vice President-Medical Affairs at GSK Plc, Chief Medical Officer at Otonomy, Inc., and VP-Medical Affairs Commercial Operations at National Accounts, Inc. He received an undergraduate degree from the University of Denver and a doctorate from The University of Colorado School of Medicine.
Former positions of Dean Hakanson
| Companies | Position | End |
|---|---|---|
| OTONOMY | Chief Tech/Sci/R&D Officer | 2018-01-30 |
| NOVARTIS AG | Corporate Officer/Principal | 2010-04-30 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2009-06-30 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2007-12-31 |
| GSK PLC | Chief Tech/Sci/R&D Officer | 2004-12-31 |
Training of Dean Hakanson
| University of Denver | Undergraduate Degree |
| The University of Colorado School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NOVARTIS AG | Health Technology |
| GSK PLC | Health Technology |
| Private companies | 3 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
| National Accounts, Inc. |
- Stock Market
- Insiders
- Dean Hakanson